Pharmaceutical

Revolution Medicines partners Royalty Pharma on $2bn funding

Revolution Medicines has partnered Royalty Pharma for $2bn to support development and commercialisation of its RAS(ON) inhibitors.

Jun 25, 2025 - 06:00
Revolution Medicines partners Royalty Pharma on $2bn funding
Revolution Medicines has partnered Royalty Pharma for $2bn to support development and commercialisation of its RAS(ON) inhibitors.
Read the original article

Tags:

Previous Article

Alzheimer’s R&D resurgence driven by $16.8bn in acquisitions in 2025YTD

Next Article

FDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoid

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

GUB-014295 by Gubra for Obesity: Likelihood of Approval

Dec 20, 2023

STAT+: Weight loss drug Wegovy improves function in people with common type of heart failure

STAT+: Weight loss drug Wegovy improves function in peo...

Aug 25, 2023

Australian CAI unveils new facility for cancer therapy development

Australian CAI unveils new facility for cancer therapy ...

Jul 17, 2023